The race against time and financial constraints is a constant struggle in the world of drug discovery. Developing life-saving medications and finding cures for debilitating diseases like cancer and degenerative conditions often requires years of painstaking research and immense financial resources.
09.08.2024
As part of our quick founder questions series - or QFQs - we spoke to Sona Chandra, President and cofounder of Pangea Bio about using AI to unlock nature’s neuroactive chemistry, working with Playfair Capital and growing a global network.
20.06.2024
We spoke to Dr Michael Chen, Co-founder and CEO at Nuclera about being selected to join Tech Nation’s Future Fifty programme, founder life and plans for the future.
28.05.2024
The 20th century was the century of chemistry and physics. Harnessing the physical properties of atoms and molecules, scientists and engineers produced ammonia fertilizer, refined petrochemicals, unleashed energy from hydrocarbons, created novel plastics, and built the atomic bomb. The 21st century will be one of biology.
23.06.2023
As part of our quick fire questions series – or QFQs – we spoke to Dr. Andy Franklyn-Miller, Chief Medical and Innovation Officer at Nuritas about intelligent ingredients, explaining peptides and proving an AI model in life science.
30.05.2023
As part of our quick fire questions series – or QFQs – we spoke to Shakiba Kaveh CEO and cofounder of Mitra Bio about molecular markers, a growth mindset and allowing consumers to measure their own biological aging.
22.10.2022
As the classic New Yorker cartoon says, ‘on the internet, nobody knows you’re a dog’. This image from as far back as 1993 outlines a key feature of (and some would say a major problem with) the internet: there is often no way to tell whether any digital identity is authentic.
04.11.2021
Every week, Maddyness curates articles from other outlets on a topic that is driving the headlines. This week, we're talking about the introduction of facial recognition software in UK schools, and the security concerns linked to this technology.
25.10.2021
Using biometrics as a means of identification and authentication has been rapidly evolving. As consumers increase their use of digital channels and platforms, protecting their privacy and personal data is critical.
20.10.2021
Earlier this year, the Bioindustry Association reported that the UK’s biotech companies are on track for a record-breaking year of fundraising, with over £830M flowing into the sector by the end of February. Compared to this time last year, the UK’s biotechs have raised more than double the amount of venture capital for new companies.
21.07.2021
We will need to restore billions of hectares of land over the coming years. Luckily, new AI and drone technology works ten times faster than planting trees by hand.
19.02.2021
Combining Oxford University research, corporate expertise and seed funding, it’s set to launch up to 20 climate startups within two years. Meet the Oxford GAV Conservation Venture Studio.
16.02.2021
The seed funding round was led by Oxford Sciences Innovation with participation from genomics and oncology experts. With this new investment, Base Genomics intends to develop its epigenetic technology for early and sensitive detection of cancer from liquid biopsy.
05.06.2020
Lifebit, a leading innovator in bioinformatics and cognitive software solutions, received a £6M Series A investment from Idinvest Partners, Pentech Ventures LLP, Beacon Capital and Connect Ventures. Lifebit aims to truly democratise access to genomics data by enabling researchers to become experts at running complex analyses and to unlock the value of this data.
04.05.2020